The present invention related to a pharmaceutical composition with anti-IL-19 antibody for suppressing bone loss, which comprises: a first antibody in an effective amount, wherein the first antibody is an anti-IL-19 antibody or the antigen binding fragment thereof, and a pharmaceutical carrier. The pharmaceutical composition for the present invention further comprises a second antibody, wherein the second antibody is an anti-IL-20 antibody, anti-IL-20R1 antibody, anti-TNFα antibody, anti-IL-20 antigen binding fragment, anti-IL-20R1 antigen binding fragment, or anti-TNFα antigen binding fragemnt. In addition, the first antibody and the second antibody for the present invention are a kind of engineered antibody such as a monoclonal antibody, a humanized antibody, a chimeric antibody, a single-chain antibody, or a domain antibody.本發明係關於一種以抗IL-19抗體治療類風濕性關節炎之醫藥組合物，該醫藥組合物係包含：有效劑量之一第一抗體，其中該第一抗體係為抗IL-19抗體或其抗原結合片段；以及一醫藥上可接受之載體。而本發明之醫藥組成物更包含一第二抗體，其中該第二抗體係為抗IL-20抗體、抗IL-20R1抗體、抗TNFα抗體、含抗IL-20抗原結合片段之抗體、含抗IL-20R1抗原結合片段之抗體、含抗TNFα抗原結合片段之抗體。此外，本發明之第一抗體及第二抗體係為一種基因工程抗體，如單株抗體、人源化抗體、嵌合抗體、單鏈抗體、或功能區塊抗體。
